
The World Health Organisation (WHO) has raised serious concerns that HIV medication shortages sparked by cuts to USAID will increase resistance to crucial treatment, The Independent can reveal.
Leading epidemiologists have raised fears that shortages could reduce the effectiveness of the most commonly used HIV drug, dolutegravir (DTG), which is used by around 27 million people. This could leave patients without an alternative treatment.